x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DIA-0243284
| Product Information | |
|---|---|
| CAS No. | 876387-05-2 |
| Synonyms | MGA-031; PRV-031 |
| SMILES | [Teplizumab] |
| Target | CD3 |
| Product Description | Teplizumab (MGA-031) is a Fc receptor non-binding anti-human CD3 monoclonal antibody. Teplizumab reduces the loss of beta-cell function. Teplizumab can be used in the research of type 1 diabetes. |
| Format & Storage | |
|---|---|
| Format | Liquid |
| Color | Colorless to light yellow |
| Purity | 99.90% |
| Shipping | Shipping with dry ice. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
Ace Therapeutics has a team of wellknown experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
